Counsyl is a reproductive genetic testing company that offers carrier screening, prenatal screening, and hereditary cancer risk assessments. The company pioneered accessible, affordable genetic testing services for family planning and hereditary disease prevention. Counsyl's key products include Foresight (expanded carrier screening), Prelude (non-invasive prenatal screening), and Reliant (hereditary cancer screening).
Counsyl has been acquired
This company is no longer available on our private secondary market.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2007
Total Funding
$256M
5 rounds
Total raised $256M across 5 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Series E
Date
November 6, 2017
Amount
$80M
Valuation
—
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| November 6, 2017 | Series E | $80M | — | Perceptive Advisors |
| September 2016 | Series D | $80M | — | Founders Fund |
| 2015 | Series C | $68M | — | David Bonderman |
Ramji Srinivasan
Co-Founder, CEO
Rishi Kacker
Co-Founder, VP Products & Technology
Eric Evans
Co-Founder, Chief Scientist
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Natera
Provider of non-invasive prenatal screening, carrier screening, and cancer genomics testing
Invitae
Genetic testing company offering carrier screening, prenatal screening, and cancer risk assessment
Myriad Genetics
Parent company post-acquisition; provides comprehensive genetic testing and cancer risk assessment
Ambry Genetics
Independent genetic testing laboratory offering diagnostic and carrier screening tests
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.